<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300469</url>
  </required_header>
  <id_info>
    <org_study_id>M05-750</org_study_id>
    <nct_id>NCT00300469</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335)
      + atorvastatin combination therapy with ABT-335 and atorvastatin monotherapy in subjects with
      multiple abnormal lipid levels in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in Triglycerides From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Total Cholesterol From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit</measure>
    <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">613</enrollment>
  <condition>Mixed Dyslipidemia</condition>
  <condition>Coronary Heart Disease</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-335 + 20 mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT-335 + 40 mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ABT-335 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mg atorvastatin monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 mg atorvastatin monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>80 mg atorvastatin monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-335</intervention_name>
    <description>135 mg, daily, 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Daily, 12 weeks, see Arm Description for dosage information</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>daily, 12 weeks, see Arm Description for placebo information</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with mixed dyslipidemia

          -  Subjects must agree to utilize adequate birth control methods and to adhere to the
             American Heart Association (AHA) diet

        Exclusion Criteria:

          -  Subjects with unstable medical conditions or medical conditions considered
             inappropriate in a clinical trial.

          -  Patients who are taking certain medications or unstable dose of specific medications.

          -  Women who are pregnant or plan on becoming pregnant, or women who are lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Global Medical Information</name>
      <address>
        <city>North Chicago</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <results_first_submitted>January 14, 2009</results_first_submitted>
  <results_first_submitted_qc>March 24, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2009</results_first_posted>
  <last_update_submitted>June 1, 2009</last_update_submitted>
  <last_update_submitted_qc>June 1, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maureen Kelly, MD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Mixed Dyslipidemia</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibric acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Four subjects were randomized but never treated: 2 were randomized but were deemed ineligible, 1 had a history of allergic reactions to statins, and 1 was noncompliant and never received study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABT-335 + 20 mg Atorvastatin</title>
          <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="P2">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="P3">
          <title>ABT-335</title>
          <description>ABT-335 monotherapy once daily</description>
        </group>
        <group group_id="P4">
          <title>20 mg Atorvastatin</title>
          <description>20 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="P5">
          <title>40 mg Atorvastatin</title>
          <description>40 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="P6">
          <title>80 mg Atorvastatin</title>
          <description>80 mg atorvastatin monotherapy once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110">For all arms, &quot;started&quot; means treated.</participants>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="112"/>
                <participants group_id="P4" count="113"/>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="104"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABT-335 + 20 mg Atorvastatin</title>
          <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="B2">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="B3">
          <title>ABT-335</title>
          <description>ABT-335 monotherapy once daily</description>
        </group>
        <group group_id="B4">
          <title>20 mg Atorvastatin</title>
          <description>20 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="B5">
          <title>40 mg Atorvastatin</title>
          <description>40 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="B6">
          <title>80 mg Atorvastatin</title>
          <description>80 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="112"/>
            <count group_id="B4" value="113"/>
            <count group_id="B5" value="109"/>
            <count group_id="B6" value="55"/>
            <count group_id="B7" value="609"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="109"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in Triglycerides From Baseline to Final Visit</title>
        <description>[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline triglyceride value and at least 1 postbaseline triglyceride value, last observation carried forward (excluding one subject with an extreme outlying value)</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Triglycerides From Baseline to Final Visit</title>
          <description>[(Week 12 triglycerides minus baseline triglycerides)/baseline triglycerides] x 100</description>
          <population>All randomized subjects with a baseline triglyceride value and at least 1 postbaseline triglyceride value, last observation carried forward (excluding one subject with an extreme outlying value)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.6" spread="3.36"/>
                    <measurement group_id="O2" value="-42.1" spread="3.40"/>
                    <measurement group_id="O3" value="-29.6" spread="3.35"/>
                    <measurement group_id="O4" value="-16.5" spread="3.31"/>
                    <measurement group_id="O5" value="-23.2" spread="3.35"/>
                    <measurement group_id="O6" value="-30.4" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide &gt;99% power to detect a 20% decrease in triglycerides relative to statin monotherapy for each combo therapy dose, assuming an SD of 30%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide &gt;99% power to detect a 20% decrease in triglycerides relative to statin monotherapy for each combo therapy dose, assuming an SD of 30%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit</title>
        <description>[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline HDL-C value and at least 1 postbasline HDL-C value, last observation carried forward (excluding 1 subject with extreme outlying value)</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit</title>
          <description>[(Week 12 HDL-C minus baseline HDL-C)/baseline HDL-C] x 100</description>
          <population>All randomized subjects with a baseline HDL-C value and at least 1 postbasline HDL-C value, last observation carried forward (excluding 1 subject with extreme outlying value)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="101"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="2.02"/>
                    <measurement group_id="O2" value="12.6" spread="2.08"/>
                    <measurement group_id="O3" value="19.9" spread="2.04"/>
                    <measurement group_id="O4" value="6.3" spread="1.96"/>
                    <measurement group_id="O5" value="5.3" spread="2.05"/>
                    <measurement group_id="O6" value="6.2" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide 99% power to detect a 13% increase in HDL-C relative to statin monotherapy for each combo therapy dose, assuming an SD of 15%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide 99% power to detect a 13% increase in HDL-C relative to statin monotherapy for each combo therapy dose, assuming an SD of 15%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit</title>
        <description>[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline LDL-C value and at least 1 postbaseline LDL-C value, last observation carried forward (excluding 1 subject with extreme outlying value)</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit</title>
          <description>[(Week 12 LDL-C minus baseline LDL-C)/baseline LDL-C] x 100</description>
          <population>All randomized subjects with a baseline LDL-C value and at least 1 postbaseline LDL-C value, last observation carried forward (excluding 1 subject with extreme outlying value)</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.7" spread="1.91"/>
                    <measurement group_id="O2" value="-35.4" spread="1.93"/>
                    <measurement group_id="O3" value="-3.4" spread="1.90"/>
                    <measurement group_id="O4" value="-37.1" spread="1.85"/>
                    <measurement group_id="O5" value="-39.7" spread="1.92"/>
                    <measurement group_id="O6" value="-46.0" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide &gt;99% power to detect a 31% decrease in LDL-C relative to ABT-335 monotherapy for each combo therapy dose, assuming an SD of 15%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An n = 92 per arm would provide &gt;99% power to detect a 31% decrease in LDL-C relative to ABT-335 monotherapy for each combo therapy dose, assuming an SD of 15%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>alpha = 0.05, all 3 primary endpoints had to show superiority of combo therapy in order to declare combo therapy successful at a given statin dose, Hochberg method for multiple comparison adjustment for 2 statin doses</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit</title>
        <description>[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline non-HDL-C value and at least 1 postbaseline non-HDL-C value, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit</title>
          <description>[(Week 12 non-HDL-C minus baseline non-HDL-C)/baseline non-HDL-C] x 100</description>
          <population>All randomized subjects with a baseline non-HDL-C value and at least 1 postbaseline non-HDL-C value, LOCF</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="102"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.8" spread="1.69"/>
                    <measurement group_id="O2" value="-42.5" spread="1.74"/>
                    <measurement group_id="O3" value="-14.8" spread="1.71"/>
                    <measurement group_id="O4" value="-35.7" spread="1.64"/>
                    <measurement group_id="O5" value="-41.7" spread="1.72"/>
                    <measurement group_id="O6" value="-45.2" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit</title>
        <description>[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline VLDL-C value and at least 1 postbaseline VLDL-C value, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit</title>
          <description>[(Week 12 VLDL-C minus baseline VLDL-C)/baseline VLDL-C] x 100</description>
          <population>All randomized subjects with a baseline VLDL-C value and at least 1 postbaseline VLDL-C value, LOCF</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.3" spread="3.72"/>
                    <measurement group_id="O2" value="-53.5" spread="3.74"/>
                    <measurement group_id="O3" value="-36.5" spread="3.66"/>
                    <measurement group_id="O4" value="-26.2" spread="3.63"/>
                    <measurement group_id="O5" value="-35.6" spread="3.66"/>
                    <measurement group_id="O6" value="-38.9" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Total Cholesterol From Baseline to Final Visit</title>
        <description>[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline total cholesterol value and at least 1 postbaseline total cholesterol value, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Total Cholesterol From Baseline to Final Visit</title>
          <description>[(Week 12 total cholesterol minus baseline total cholesterol)/baseline total cholesterol] x 100</description>
          <population>All randomized subjects with a baseline total cholesterol value and at least 1 postbaseline total cholesterol value, LOCF</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="105"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="1.32"/>
                    <measurement group_id="O2" value="-34.6" spread="1.33"/>
                    <measurement group_id="O3" value="-10.1" spread="1.32"/>
                    <measurement group_id="O4" value="-29.6" spread="1.29"/>
                    <measurement group_id="O5" value="-33.8" spread="1.31"/>
                    <measurement group_id="O6" value="-38.2" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit</title>
        <description>[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline ApoB value and at least 1 postbaseline ApoB value, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit</title>
          <description>[(Week 12 Apo B minus baseline Apo B)/baseline Apo B] x 100</description>
          <population>All randomized subjects with a baseline ApoB value and at least 1 postbaseline ApoB value, LOCF</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="104"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.0" spread="1.49"/>
                    <measurement group_id="O2" value="-37.1" spread="1.52"/>
                    <measurement group_id="O3" value="-12.4" spread="1.49"/>
                    <measurement group_id="O4" value="-32.9" spread="1.46"/>
                    <measurement group_id="O5" value="-35.3" spread="1.50"/>
                    <measurement group_id="O6" value="-40.3" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit</title>
        <description>[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100</description>
        <time_frame>Baseline to 12 Weeks (Final Visit)</time_frame>
        <population>All randomized subjects with a baseline hsCRP value and at least 1 postbaseline hsCRP value, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-335 + 20 mg Atorvastatin</title>
            <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O2">
            <title>ABT-335 + 40 mg Atorvastatin</title>
            <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
          </group>
          <group group_id="O3">
            <title>ABT-335</title>
            <description>ABT-335 monotherapy once daily</description>
          </group>
          <group group_id="O4">
            <title>20 mg Atorvastatin</title>
            <description>20 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O5">
            <title>40 mg Atorvastatin</title>
            <description>40 mg atorvastatin monotherapy once daily</description>
          </group>
          <group group_id="O6">
            <title>80 mg Atorvastatin</title>
            <description>80 mg atorvastatin monotherapy once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Final Visit</title>
          <description>[(Week 12 hsCRP minus baseline hsCRP)/baseline hsCRP] x 100</description>
          <population>All randomized subjects with a baseline hsCRP value and at least 1 postbaseline hsCRP value, LOCF</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="104"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.2" spread="24.76" lower_limit="-49.7" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-42.9" spread="25.11" lower_limit="-56.4" upper_limit="-21.2"/>
                    <measurement group_id="O3" value="-12.4" spread="24.65" lower_limit="-41.2" upper_limit="42.8"/>
                    <measurement group_id="O4" value="-29.6" spread="24.18" lower_limit="-48.3" upper_limit="14.7"/>
                    <measurement group_id="O5" value="-30.3" spread="25.08" lower_limit="-51.7" upper_limit="-2.4"/>
                    <measurement group_id="O6" value="-31.9" spread="34.50" lower_limit="-57.5" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABT-335 + 20 mg Atorvastatin</title>
          <description>ABT-335 + 20 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="E2">
          <title>ABT-335 + 40 mg Atorvastatin</title>
          <description>ABT-335 + 40 mg atorvastatin combination therapy once daily</description>
        </group>
        <group group_id="E3">
          <title>ABT-335</title>
          <description>ABT-335 monotherapy once daily</description>
        </group>
        <group group_id="E4">
          <title>20 mg Atorvastatin</title>
          <description>20 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="E5">
          <title>40 mg Atorvastatin</title>
          <description>40 mg atorvastatin monotherapy once daily</description>
        </group>
        <group group_id="E6">
          <title>80 mg Atorvastatin</title>
          <description>80 mg atorvastatin monotherapy once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="2"/>
                <counts group_id="E3" subjects_affected="3"/>
                <counts group_id="E4" subjects_affected="2"/>
                <counts group_id="E5" subjects_affected="2"/>
                <counts group_id="E6" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50"/>
                <counts group_id="E2" subjects_affected="50"/>
                <counts group_id="E3" subjects_affected="50"/>
                <counts group_id="E4" subjects_affected="45"/>
                <counts group_id="E5" subjects_affected="57"/>
                <counts group_id="E6" subjects_affected="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Not to publish or present the results before the publication of the multi-center investigator paper, but in no event shall be so restricted after the expiration of twelve (12) months from completion of the studies at all sites. Any presentation or publication to be submitted to Sponsor (in draft of the same) for Sponsor review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Specialist</name_or_title>
      <organization>Abbott</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

